

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1612

Wagner, Jürgen et al.

Examiner: Webb, Walter E

INTERNATIONAL APPLICATION NO: PCT/EP2005/003663

FILED: April 07, 2005

U S. APPLICATION NO: 10/599697

35 USC §371 DATE: October 05, 2006

FOR: Protein Kinase C Inhibitors for the Treatment of Autoimmune
Diseases and of Transplant Rejection

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ supplemental to the Information Disclosure Statement filed March 30, 2009.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to
Deposit Account No. 19-0134 in the name of Novartis.

☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R.
§1.97(c) or 37 C.F.R. §1.97(d).


☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the
references cited on the attached form(s) PTO-1449.

☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application
and indicate that each reference was considered by returning a copy of the initialed PTO 1449
form(s).

Respectfully submitted,



Leslie Fischer
Attorney for Applicant
Reg. No. 58,393

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9308

Date: 12/1/10